{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:20:19Z","timestamp":1790882419282,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,8,7]],"date-time":"2007-08-07T00:00:00Z","timestamp":1186444800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2007,11,23]]},"DOI":"10.1007\/s11255-007-9254-2","type":"journal-article","created":{"date-parts":[[2007,8,6]],"date-time":"2007-08-06T12:36:35Z","timestamp":1186403795000},"page":"1251-1256","source":"Crossref","is-referenced-by-count":10,"title":["Effects of parathyroidectomy on bone remodeling markers and vitamin D status in patients with chronic kidney disease\u2013mineral and bone disorder"],"prefix":"10.1007","volume":"39","author":[{"given":"Barbara Santarosa Emo","family":"Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria Affonso","family":"Moyses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Jorgetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00edgia Ara\u00fajo","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,8,7]]},"reference":[{"key":"9254_CR1","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/ndt\/14.9.2085","volume":"14","author":"K Amann","year":"1999","unstructured":"Amann K, Gross ML, London GM, Ritz E (1999) Hyperphosphataemia\u2014a silent killer of patients with renal failure? Nephrol Dial Transplant 14:2085\u20132087","journal-title":"Nephrol Dial Transplant"},{"key":"9254_CR2","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0272-6386(97)90459-5","volume":"29","author":"MM Salem","year":"1997","unstructured":"Salem MM (1997) Hyperparathyroidism in the hemodialysis population: a survey of 612 patients. Am J Kidney Dis 29:862\u2013865","journal-title":"Am J Kidney Dis"},{"key":"9254_CR3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/ndt\/gfg144","volume":"18","author":"H Reichel","year":"2003","unstructured":"Reichel H, Esser A, Hoth HJ, Schmidt-Gayk H (2003) Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 18:759\u2013768","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 85","key":"9254_CR4","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1046\/j.1523-1755.63.s85.23.x","volume":"63","author":"R Jofr\u00e9","year":"2003","unstructured":"Jofr\u00e9 R, G\u00f3mez JML, Men\u00e1rgues J et al (2003) Parathyroidectomy: who and when? Kidney Int 63(suppl 85):S97\u2013S100","journal-title":"Kidney Int"},{"issue":"2A","key":"9254_CR5","first-page":"1027","volume":"23","author":"JM Halleen","year":"2003","unstructured":"Halleen JM (2003) Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorpition. Anticancer Res 23(2A):1027\u20131029","journal-title":"Anticancer Res"},{"issue":"1","key":"9254_CR6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/clinchem\/47.1.74","volume":"47","author":"AJ Janckila","year":"2001","unstructured":"Janckila AJ, Takahashi K, Sun SZ, Yam LT (2001) Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 47(1):74\u201380","journal-title":"Clin Chem"},{"issue":"10","key":"9254_CR7","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1359\/jbmr.2003.18.10.1892","volume":"18","author":"AJ Janckila","year":"2003","unstructured":"Janckila AJ, Halleen JM (2003) Introduction: recent advances in TRAP\/PAP biochemistry, molecular biology, and clinical application. J Bone Miner Res 18(10):1892\u20131893","journal-title":"J Bone Miner Res"},{"key":"9254_CR8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet WS, Lacey DL, Dunstan CR et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309\u2013319","journal-title":"Cell"},{"issue":"3","key":"9254_CR9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/ajkd.2002.31402","volume":"39","author":"JJ Kazama","year":"2002","unstructured":"Kazama JJ, Shigematsu T, Yano K et al (2002) Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 39(3):525\u2013532","journal-title":"Am J Kidney Dis"},{"key":"9254_CR10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ndt\/17.2.233","volume":"17","author":"G Coen","year":"2002","unstructured":"Coen G, Ballanti P, Balducci A et al (2002) Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 17:233\u2013238","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"9254_CR11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00223-005-0161-1","volume":"78","author":"J Padagas","year":"2006","unstructured":"Padagas J, Colloton M, Shalhoub V et al (2006) The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. Calcif Tissue Int 78(1):35\u201344","journal-title":"Calcif Tissue Int"},{"key":"9254_CR12","unstructured":"Hannan FM, Fairney A, Kyd P, Patel A (2003) Serum osteoprotegerin as a novel marker of metabolic bone disease. In: 24th Annual Meeting of the ASBMR, Minneapolis, NM, USA, SA145"},{"issue":"10","key":"9254_CR13","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1515\/CCLM.2002.177","volume":"40","author":"I Avbersek-Luznik","year":"2002","unstructured":"Avbersek-Luznik I, Malesic I, Rus I, Marc J (2002) Increased levels of osteoprotegerin in hemodialysis patients. Clin Chem Lab Med 40(10):1019\u20131023","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"9254_CR14","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1053\/ajkd.2002.31409","volume":"39","author":"M Haas","year":"2002","unstructured":"Haas M, Leko-Mohr Z, Roschger P et al (2002) Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis 39(3):580\u2013586","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"9254_CR15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1053\/ajkd.2002.35692","volume":"40","author":"M Ueda","year":"2002","unstructured":"Ueda M, Inaba M, Okuno S et al (2002) Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis 40(4):802\u2013809","journal-title":"Am J Kidney Dis"},{"key":"9254_CR16","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1046\/j.1523-1755.1999.00461.x","volume":"55","author":"P Ure\u00f1a","year":"1999","unstructured":"Ure\u00f1a P, Vernejoul MC (1999) Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 55:2141\u20132156","journal-title":"Kidney Int"},{"key":"9254_CR17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000013602","volume":"20","author":"G Coen","year":"2000","unstructured":"Coen G, Mantella D, Calabria S et al (2000) Urinary deoxipyridinoline excretion for the evaluation of bone turnover in chronic renal failure. Am J Nephrol 20:283\u2013290","journal-title":"Am J Nephrol"},{"key":"9254_CR18","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1046\/j.1523-1755.1999.00480.x","volume":"55","author":"A Ghazali","year":"1999","unstructured":"Ghazali A, Fardellone P, Pruna A et al (1999) Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser\u2019s zones independent of calcitriol? Kidney Int 55:2169\u20132177","journal-title":"Kidney Int"},{"issue":"4","key":"9254_CR19","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/089686080502500411","volume":"25","author":"N Shah","year":"2005","unstructured":"Shah N, Bernardini J, Piraino B (2005) Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients. Perit Dial Int 25(4):362\u2013366","journal-title":"Perit Dial Int"},{"key":"9254_CR20","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/ndt\/17.11.1875","volume":"17","author":"JB Cannata-And\u00eda","year":"2002","unstructured":"Cannata-And\u00eda JB, Gomez-Alonso C (2002) Vitamin D deficiency: a neglected aspect of disturbed calcium metabolism in renal failure. Nephrol Dial Transplant 17:1875\u20131878","journal-title":"Nephrol Dial Transplant"},{"key":"9254_CR21","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1046\/j.1523-1755.63.s85.11.x","volume":"85","author":"C Gomez-Alonso","year":"2003","unstructured":"Gomez-Alonso C, Naves-Diaz ML, Fernandez-Martin JL et al (2003) Vitamin D status and secondary hyperparathyroidism: the importance of 25-hydroxyvitamin D cut-off levels. Kidney Int Suppl 85:S44\u2013S48","journal-title":"Kidney Int Suppl"},{"issue":"suppl 1","key":"9254_CR22","first-page":"S1","volume":"39","author":"National Kidney Foundation","year":"2002","unstructured":"National Kidney Foundation (2002) K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 39(suppl 1):S1\u2013S8","journal-title":"Am J Kidney Dis"},{"key":"9254_CR23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3109\/00365519109104560","volume":"51","author":"L Scarnecchia","year":"1991","unstructured":"Scarnecchia L, Minisola S, Pacitti MT et al (1991) Clinical usefulness of serum tartrateresistant acid phosphatase activity determination to evaluate bone turnover. Scand J Clin Lab Invest 51:517\u2013524","journal-title":"Scand J Clin Lab Invest"},{"key":"9254_CR24","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1093\/clinchem\/45.12.2150","volume":"45","author":"YR Nakasato","year":"1999","unstructured":"Nakasato YR, Janckila AJ, Halleen JM, Vaananen HK, Walton SP, Yam LT (1999) Clinical significance of immunoassays for type-5 tartrateresistant acid phosphatase. Clin Chem 45:2150\u20132157","journal-title":"Clin Chem"},{"key":"9254_CR25","first-page":"259","volume":"20","author":"E Lopes Gavilanes","year":"1994","unstructured":"Lopes Gavilanes E, Parra EG, de La Piedra C, Caramelo C, Rapado A (1994) Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure. Miner Electrolyte Metab 20:259\u2013264","journal-title":"Miner Electrolyte Metab"},{"issue":"9","key":"9254_CR26","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1093\/ndt\/13.9.2394","volume":"13","author":"R Lorho","year":"1998","unstructured":"Lorho R, Mourad G, Couret I, Argiles A (1998) The dialysis patient with persisting elevation of bone alkaline phosphatase after parathyroidectomy. Nephrol Dial Transplant 13(9):2394\u20132396","journal-title":"Nephrol Dial Transplant"},{"key":"9254_CR27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.mnh.0000133982.40182.8a","volume":"13","author":"JJ Kazama","year":"2004","unstructured":"Kazama JJ (2004) Osteoprotegerin and bone mineral metabolism in renal failure. Curr Opin Nephrol Hypertens 13:411\u2013415","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"9254_CR28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1681\/ASN.2005030260","volume":"17","author":"M Morena","year":"2006","unstructured":"Morena M, Terrier N, Jaussent I et al (2006) Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 17(1):262\u2013270","journal-title":"J Am Soc Nephrol"},{"key":"9254_CR29","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1053\/j.ajkd.2005.02.029","volume":"45","author":"RE LaClair","year":"2005","unstructured":"LaClair RE, Hellman RN, Karp SN et al (2005) Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 45:1026\u20131033","journal-title":"Am J Kidney Dis"},{"key":"9254_CR30","unstructured":"Wong J, Tran J, Thomas D et al (2002) Hipovitaminosis D (HVD) exarcebates secondary hyperparthyreoidism early in the course of chronic kidney disease. In: Proceeding of the Endocrine Society\u2019s 84th annual meeting, June 19\u201322, p450, 2\u2013557"},{"issue":"suppl 6","key":"9254_CR31","doi-asserted-by":"crossref","first-page":"1678S","DOI":"10.1093\/ajcn\/80.6.1678S","volume":"80","author":"MF Holick","year":"2004","unstructured":"Holick MF (2004) Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 80(suppl 6):1678S\u20131688S","journal-title":"Am J Clin Nutr"},{"key":"9254_CR32","first-page":"391","volume":"7","author":"GG Schwartz","year":"1998","unstructured":"Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF (1998) Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 7:391\u2013395","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"9254_CR33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0735-1097(02)02624-4","volume":"4","author":"A Zittermann","year":"2003","unstructured":"Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, K\u00f6rfer R, Stehle P (2003) Low vitamin D status (a contributing factor in the pathogenesis of congestive heart failure?). J Am Coll Cardiol 4:105\u2013112","journal-title":"J Am Coll Cardiol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-007-9254-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-007-9254-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-007-9254-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T17:00:48Z","timestamp":1587834048000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-007-9254-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,7]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,11,23]]}},"alternative-id":["9254"],"URL":"https:\/\/doi.org\/10.1007\/s11255-007-9254-2","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,7]]}}}